The 340B Drug Pricing Program has been making health policy headlines in Washington. Much of the interest centers on potential program impacts as Congress considers radical changes to the 340B Program, which is a financial health policy key that enables our nation’s community health centers to keep their doors open. With this renewed attention comes renewed confusion, and myths about the program continue to persist, often overshadowing the real-world impact that 340B has on community health centers (CHCs), their patients and communities.
To help cut through the noise, Community Health Centers Unfiltered tackled these myths in a special 5-part podcast series, featuring Amanda Pears Kelly, CEO of Advocates for Community Health, and Elizabeth Lee, a leading 340B policy expert, and Managing Director of Continuum Health Group. Together, they dug into five of the most common myths circulating about the program, and set the record straight.
Here’s a closer look at each myth and the facts to understand.
Myth #1: “The 340B Program Is Exploding”
Opponents of the 340B program often suggest that 340B is growing out of control. But what does “exploding” really mean?
The program has grown over the past decade, Elizabeth points out, but primarily because more eligible providers are participating to meet growing community health needs, not because of reckless expansion. Enrollment trends reflect the widening gaps in the health care system: rising drug prices, increasing patient demand, and more hospitals and health centers serving high-need populations. Explosion is really a misperception because the program is working as intended.
CHCs, in particular, represent a stable, mission-driven portion of the program. Their participation isn’t about profit; it’s about serving patients and expanding programs and services that aren’t covered under typical fee-for-service models. For some CHCs, 340B is also about survival. They use 340B savings to stretch scarce resources, offer affordable medications, and ensure that services are available in areas where options are already limited.
Myth #2: “340B Influences Clinical Decision-Making”
One persistent misconception is that 340B somehow encourages health care providers to prescribe more expensive drugs to widen the savings gap. But the evidence simply doesn’t add up.
Prescribing decisions at CHCs are driven by clinical needs, patient safety, and evidence-based care, notes Elizabeth, not financial incentives. Health centers follow strict compliance standards and are mission-bound to prioritize patient well-being above all else.
In fact, 340B often increases patients’ ability to receive essential treatments. Elizabeth and Amanda discuss how a health center might use 340B savings to add behavioral health services or expand chronic disease management, initiatives that improve patients’ health and outcomes.
Myth #3: “340B Dollars Are Wasted”
Critics often ask: “Where does the money go?” The answer is clear and consistent: 340B savings are reinvested directly back into patient care.
Hear how health centers rely on these savings to:
- Provide discounted or free medications
- Expand dental, behavioral health, and vision services
- Offer transportation assistance
- Launch mobile clinics
- Support community outreach and education programs
These are services that would not exist in many communities without 340B. Cutting or limiting the program would mean fewer care options, longer wait times, and reduced access for patients already facing significant barriers. For many health centers, 340B is the difference between offering comprehensive care or making painful cuts.
Myth #4: “HRSA Isn’t Providing Oversight”
Some critics paint 340B as an unmonitored program, but the truth is that the Health Resources and Services Administration (HRSA) doesn’t have authority to issue regulations for the entire program. HRSA does provide oversight and guidance and has asked Congress for full regulatory authority.
The Health Resources and Services Administration (HRSA) conducts:
- Routine audits of covered entities
- Ongoing monitoring of program integrity
- Enforcement of compliance requirements
HRSA takes 340B oversight seriously. They maintain detailed records, implement internal controls, and invest in compliance staff and systems. While oversight needs to evolve as the program grows, the idea that 340B is an unregulated “Wild West” simply isn’t accurate.
Myth #5: “Covered Entities Don’t Support Reform”
Another 340B misconception is that covered entities, including CHCs, oppose any efforts to change or strengthen the program. Turns out the reality is quite the opposite.
Amanda notes that health centers actively support reforms that protect program integrity, modernize operations, and preserve access for patients. They regularly collaborate with policymakers, federal agencies, and industry partners on solutions that ensure 340B remains strong, transparent, and accountable.
What don’t they support? Reforms that restrict access, undermine patient care, or shift power to drug manufacturers at the expense of the communities that 340B was originally designed to support.
Why the Truth on 340B Matters
The 340B program is more than an abstract policy debate. It’s a lifeline for millions of patients and the health centers that serve them. Dispelling myths is essential to protecting a critical program that strengthens communities, expands healthcare, and builds healthier futures.
As Amanda and Elizabeth remind us, 340B works because it allows mission-driven providers to do more with less. In a health care landscape where resources are stretched and needs continue to rise, that mission is more important than ever.
Check out all the 340B mythbuster clips on the playlist.